Reply to Swart and Korf
To the Editor: We thank Swart and Korf for their interest in our method of correction of plasma tracer concentrations for the presence of labelled metabolites. We also appreciate the opportunity to clarify a method which still may be of service to researchers, who, for a variety of reasons, do not make this correction by chemical assay of plasma samples.
Remark 1 is misleading since we made no as sumption about the particular properties of the plasma and brain metabolites of NMSP, and did not assume that the correction for metabolites would still necessarily be valid if metabolites passed the blood brain barrier and were bound reversibly to receptors in the tissue (1).
The core of the criticism of Swart and Korf is contained in their equation 5 which argues that the corrected plasma concentration, Ca(t) is the "true" corrected concentration only when the suspected metabolites do not enter brain tissue and when other labelled metabolites are not formed in the tis sue. These conditions agree completely with the stated intention of the metabolite correction, "to correct for the metabolites of the second type," i.e., metabolites "that do not achieve equilibrium during the PET scan." To this we can now add the obvious comment that the correction only accounts for these metabolites to the extent that these me tabolites do not achieve this equilibrium. In other words, the degree of correction of blood concentra tions depends on the quantity of metabolites that do enter the brain and thus is only complete when the metabolites do not enter the brain at all. The test of this correction method is the comparison with chemically assayed concentrations which were per formed both in the original paper and numerous times afterward. It is gratifying to report that the agreement, rather fortuitously, has always been excellent. In conclusion, we never suggested that the metabolite correction described in the paper would always be valid, but we have observed that it is valid in all of the cases of formation of NMSP metabolites in human plasma investigated by us. We have developed a specific and sensitive as say for HPLC measurements of labeled Methylspiperone (I l C-NMSP) metabolites beyond those published. We are happy to show the result of these observations in the form of the following graph which displays model corrected concentra tions (abscissa) v.s. HPLC concentration (ordinate) and the line of identity. The coefficient of this cor relation was 0.98 ( Fig. 1) . The agreement confirms N, number of pre-and post-haloperidol PET scans, each subject got 2 scans. Note: At most, a 1-2% difference between before and after metabolite correc tion was observed in a direction opposite to that predicted by Swart and Korf. More important, ANOV A (ANOV A was a 3 x 2 x 2 repeated measures AOV with diagnosis (3 levels) as between group factor; before and after metabolite correction, pre-and post-haloperidol as the within group factors.) demonstrated no main effect for diagnosis nor significant interaction of other factors with diag nosis (i.e., no bias across diagnoses). Multiple comparisons by t tests by Bonfer roni corrections for the partition coefficients before and after correction, and for the ratio of these coefficients were not significant across each patient nor across each diagnosis. Ninety-five percent confidence limits (repeated measures ANOV A) on the ratio of the before and after partition coefficients (pooled across diagnostic groups) for pre haloperidol studies was only 1. 02 ± 0.05 and for post haloperidol studies, 1.01 ± 0.04, dF = 23.
the assumption that labelled metabolites of ll C _ NMSP do not significantly enter the brain. In fact, this is also the conclusion drawn in the paper, that "since the model corrected and HPLC corrections were similar, the concentration of metabolites in the brain was probably low" (WEA, p. 142). This con clusion agrees with ongoing studies of guinea pig brain in which only 1% of the brain radioactivity was found to be metabolites. More important, the agreement continued in several studies of normal volunteers and patients that included drug-naive schizophrenics, patients with bipolar illness, sub jects undergoing normal aging. The continued agreement indicates that there is no bias of the model-dependent correction for metabolites that can account for the 2.6 fold elevation of Bmax pre viously reported for drug-naive schizophrenics (2).
Remark 2 suggests that the estimation of the ap parent partition coefficient is incorrect in the pres ence of significant metabolism of the tracer in plasma, even when the metabolites do not enter the brain. Since k3 is ultimately calculated from the ap parent partition coefficient (Eq. 26, WEA), an un derestimated apparent partition coefficient resulting from tracer metabolism would tend to cause over estimates of k3 in proportion to the underestimated values of the apparent partition coefficient. How ever, the observation that model and HPLC correc tions are similar, and the fact that the apparent par tition coefficient is determined after the metabolite correction, and thus does not depend on the pres ence of metabolites, makes this criticism invalid in practice, although theoretically possible.
The careful reader will note that the procedure of determining the apparent coefficient after the metabolite correction represents an inversion of the procedural steps labelled a and b (WEA, p. 139). This resolution was introduced for the reasons now outlined by Swart and Korf and used in all subse quent studies which do not therefore suffer from a bias on the basis of the metabolite correction.
We have compared the apparent partition coeffi cients before and after model correction of the plasma metabolites. The modest differences (1-2%) between the apparent partition coefficient deter mined before and after model correction in the same or across subjects were not significant by multiple t test comparisons. Furthermore, the ratio of parti tion coefficient before and after metabolite correc tion were not significant across each patient or di agnosis (see Table 1 ). The magnitude of the error incurred may depend on the shape of the input curve, as well as on the rate of metabolism. How ever, we were not able to verify the conclusions illustrated in Fig. 1 (Swart and Kort) because no input curve was provided.
In closing, we appreciate the opportunity to clar ify points about our model, and to provide addi tional evidence as validation of the assumptions dis cussed.
